Item 5. OTHER INFORMATION

Rule 10b5-1 Plans

On April 28, 2025, Gary S. Guthart, Ph.D., who was then the Company’s Chief Executive Officer and a member of the Company’s Board of Directors and who now serves as Executive Chair of the Board of Directors, adopted a Rule 10b5-1 trading plan. Dr. Guthart’s trading plan provides for (i) potential exercises of vested stock options to purchase up to 130,893 shares of the Company’s common stock, (ii) potential sales of shares of the Company’s common stock received upon such exercises to cover exercise costs, estimated tax withholding amounts, and customary brokerage fees as well as potential additional sales of such shares, (iii) the potential donation of 10,500 shares of the Company’s common stock from a trust in which Dr. Guthart is a trustee, and (iv) potential sales of up to 8,400 shares of the Company’s common stock held by trusts in which the beneficiaries are children of Dr. Guthart, until April 28, 2026. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding transactions in the Company’s securities.

On April 29, 2025, Craig H. Barratt, Ph.D., a member of the Company’s Board of Directors, adopted a Rule 10b5-1 trading plan. Dr. Barratt’s trading plan provides for the potential exercise and sale of up to 2,943 shares of the Company’s common stock subject to stock options until April 29, 2026. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding transactions in the Company’s securities.

On May 20, 2025, Jamie E. Samath, the Company’s Chief Financial Officer, adopted a Rule 10b5-1 trading plan. Mr. Samath’s trading plan provides for the potential sale of up to 12,379 shares of the Company’s common stock, including the potential exercise and sale of up to 5,381 shares of the Company’s common stock subject to stock options, until May 20, 2026. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding transactions in the Company’s securities.

On May 21, 2025, Fredrik C. Widman, the Company’s Corporate Controller and Principal Accounting Officer, adopted a Rule 10b5-1 trading plan. Mr. Widman’s trading plan provides for the potential sale of up to 8,714 shares of the Company’s common stock, including the potential exercise and sale of up to 7,284 shares of the Company’s common stock subject to stock options, until May 21, 2026. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding transactions in the Company’s securities.

On May 30, 2025, Henry H. Charlton, the Company’s Chief Commercial and Marketing Officer, adopted a Rule 10b5-1 trading plan. Mr. Charlton’s trading plan provides for the potential sale of up to 22,731 shares of the Company’s common stock, including the potential exercise and sale of up to 18,000 shares of the Company’s common stock subject to stock options, until June 1, 2026. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding transactions in the Company’s securities.

On June 4, 2025, Amy L. Ladd, M.D., a member of the Company’s Board of Directors, adopted a Rule 10b5-1 trading plan. Dr. Ladd’s trading plan provides for the potential sale of up to 671 shares of the Company’s common stock until June 4, 2026. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding transactions in the Company’s securities.

On June 11, 2025, David J. Rosa, who was then the Company’s President and a member of the Company’s Board of Directors and who now serves as the Company’s Chief Executive Officer and a member of the Company’s Board of Directors, adopted a Rule 10b5-1 trading plan. Mr. Rosa’s trading plan provides for the potential exercise and sale of up to 27,000 shares of the Company’s common stock subject to stock options until June 11, 2026. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding transactions in the Company’s securities.